Previous Close | 157.06 |
Open | 156.35 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1000 |
Day's Range | 153.95 - 156.35 |
52 Week Range | 130.96 - 182.89 |
Volume | |
Avg. Volume | 5,642,011 |
Market Cap | 274.31B |
Beta (5Y Monthly) | 0.59 |
PE Ratio (TTM) | 46.79 |
EPS (TTM) | 3.32 |
Earnings Date | Jul 25, 2024 - Jul 29, 2024 |
Forward Dividend & Yield | 6.20 (3.95%) |
Ex-Dividend Date | Apr 12, 2024 |
1y Target Est | 183.11 |
AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will be showcased across three oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024). AbbVie's ADCs are designed to target unique protein biomarkers such as c-Met (MET protein) and SEZ6 (seizure-related homolog 6 protein), which are over-expressed across various tumor types. By utilizing these biomarkers as targets, ADCs are
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the acquisition, Landos is now part of AbbVie.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.